Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

Sermorelin

Investigational

GH Secretagogue · Compounded (historical innovator: Serono — Geref)

Synthetic analog of the first 29 amino acids of growth hormone releasing hormone (GHRH). Previously FDA-approved as Geref; withdrawn from the US market in 2008 for commercial reasons, not safety. Currently available via compounding pharmacies.

About

Mechanism

GHRH analog (GRF 1-29). Binds pituitary GHRH receptors to stimulate endogenous growth hormone release in a pulsatile, physiological pattern. Preserves the GH-IGF-1 negative feedback loop.

Half-Life

~10-20 minutes (GHRH analog, rapid clearance)

Route

subcutaneous

Frequency

Daily before bed

Clinical Dosing

200-500 mcgdaily before bed

Geref (Serono) was withdrawn from the US market in 2008 for commercial reasons. Not currently an FDA-approved product; available via compounding pharmacies.

Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.

Regulatory Status

FDA Category

Previously FDA-approved (Geref, withdrawn 2008). Not on FDA Category 2 list.

Reclassification

stable

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Community Titration

Source: Geref prescribing information (historical); Walker 2006 review

Dose	Duration	Draw (2 mg vial in 2mL)	Notes
200 mcg	2 weeks	0.20 mL (20 units)	Initial dose at bedtime, subcutaneous
300 mcg	Maintenance	0.30 mL (30 units)	Typical maintenance range (200-500 mcg nightly)

Available Vial Sizes

2 mg

2 mg vial

5 mg

5 mg vial

9 mg

9 mg vial

15 mg

15 mg vial

Citations

[1]Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Endocrinology, 65(4), 413-423. Link(Reviewed: 2026-04-14)